Biocept Announces Clinical Validation and Commercial Launch of its Target Selector(TM) Multi-Gene Liquid Biopsy Panel for Lung Cancer

Stock Information for Biocept Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biocept Inc.

Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
Biocept Reports Second Quarter 2019 Financial Results
Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
Biocept Announces Commercial Launch of Target Selector(TM) NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4
Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
Biocept Reports First Quarter 2019 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.